candesartan has been researched along with Adenocarcinoma, Clear Cell in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effects of AT1 receptor blocker candesartan were evaluated in a mouse model of peritoneal carcinomatosis." | 3.75 | Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. ( Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinami, S; Kinoshita, J; Ninomiya, I; Ohta, T; Yagi, Y; Yashiro, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, J | 1 |
| Fushida, S | 1 |
| Harada, S | 1 |
| Yagi, Y | 1 |
| Fujita, H | 1 |
| Kinami, S | 1 |
| Ninomiya, I | 1 |
| Fujimura, T | 1 |
| Kayahara, M | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Ohta, T | 1 |
1 other study available for candesartan and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Angiotensin II; A | 2009 |